Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Coherus Oncology, Inc.NASDAQ: CHRS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $20.66M fell 11.4% year over year, behind the +17.6% change in trailing-twelve-month research & development. Sequentially, it fell 31.3% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.

Context

  • Research & development amounted to 248.9% of revenue in FY2025, up 213.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -11.4% toward the trailing-twelve-month pace of +17.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.66M-31.3% QoQ
Last fiscal yearDec 2025
$104.96M+12.5% YoY
LTMMar 2026
$102.32M+17.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year+12.5%——
3-year CAGR-19.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
104.96M USD
Year-over-year change
+12.5%
4-year CAGR
-26.7%

Research & Development vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 research & development of $102.32M is the 2nd highest of the 11 companies compared; the peer median is $47.33M.
  • Its year-over-year change of +17.6% is the 6th highest of 11, against a peer median of +26.6%.
  • Research & development amounts to 218.2% of revenue for CHRS, versus a peer median of 223.4%.
CHRS Competitors Peer median
Research & Development for CHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M +11.4%-23.3%327.7%
CHRSCoherus Oncology, Inc.LTM Mar 2026$102.32M +17.6%-19.3%218.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M -50.0%-40.2%104.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M +74.4%+17.0%93235.6%
CDXSCodexis, Inc.LTM Mar 2026$47.7M -0.5%-13.2%61.1%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M +41.8%+36.4%—
OABIOmniAb, Inc.LTM Mar 2026$44.75M -15.8%-0.4%154.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M +47.2%-19.1%—
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$21.52M +58.7%-13.4%28.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M +68.3%+29.6%902.4%
Peer median (excluding CHRS) $47.33M+26.6%-8.6%223.4%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.